The University of Chicago, Chicago, IL
Richard A. Larson , Andreas Hochhaus , Giuseppe Saglio , Dong-Wook Kim , Saengsuree Jootar , Philipp D. Le Coutre , Josy Reiffers , Ricardo Pasquini , Stuart L. Goldberg , Richard E. Clark , Charisse N. Kemp , Xiaolin Fan , Hans D. Menssen , Timothy P. Hughes , Hagop M. Kantarjian
Background: In the 3-y follow-up (f/u) of ENESTnd, NIL demonstrated superior rates of molecular response and reduced progression to accelerated phase/blast crisis (AP/BC) vs IM. Here, we report results with a minimum f/u of 4 y. Methods: 846 adults with newly diagnosed Philadelphia chromosome–positive CML-CP were randomized to receive NIL 300 mg twice daily (BID; n = 282), NIL 400 mg BID (n = 281), or IM 400 mg once daily (QD; n = 283). Results: NIL continued to demonstrate higher rates of major molecular response (MMR; ≤ 0.1% BCR-ABLIS), MR4 (≤ 0.01%IS), and MR4.5 (≤ 0.0032%IS) vs IM (Table). No new progressions have occurred on treatment on any arm since the 2-y analysis. NIL had significantly lower rates of progression to AP/BC on treatment (n = 2, 3, and 12 on NIL 300 mg BID, 400 mg BID, and IM, respectively) and when including f/u after discontinuation (n = 9, 6, and 19 on NIL 300 mg BID, 400 mg BID, and IM, respectively) and higher overall survival (OS) vs IM. By 4 y, half as many pts acquired new BCR-ABL mutations on study with NIL vs IM (n = 12, 11, and 22 on NIL 300 mg BID, 400 mg BID, and IM, respectively). Since the 3-y analysis, 2 new mutations (1 pt with T315I on NIL 300 mg BID; 1 pt with F317L on IM) were reported. Safety profiles of both drugs were consistent with previous ENESTnd analyses. By 4 y, peripheral arterial occlusive disease (PAOD) events were reported in 4 and 5 pts in the NIL 300 mg BID, and 400 mg BID arms, respectively. No pt in the IM arm had a PAOD event. Conclusions: ENESTnd 4-y data continue to demonstrate the superiority of NIL over IM for achieving deeper responses with lower risk of progression, supporting the use of NIL as frontline therapy in CML-CP. Clinical trial information: NCT00471497.
NIL 300 mg BID (n = 282) |
NIL 400 mg BID (n = 281) |
IM 400 mg QD (n = 283) |
|
---|---|---|---|
Response by 4 y, % (P value vs IM) | |||
MMR | 76 ( < .0001) | 73 ( < .0001) | 56 |
MR4 | 56 ( < .0001) | 50 ( < .0001) | 32 |
MR4.5 | 40 (< .0001) | 37 (.0002) | 23 |
4-y freedom from progression to AP/BC,a % (P value vs IM) |
|||
On core treatment | 99.3 (.0059) | 98.7 (.0185) | 95.2 |
On core or extension treatment or during f/u after discontinuation |
96.7 (.0497) | 97.8 (.0074) | 93.1 |
4-y OS,a % | |||
All deaths | 94.3 (.4636) | 96.7 (.0498) | 93.3 |
Pts with BCR-ABL mutations acquired on study, n |
|||
Any | 12 | 11 | 22 |
T315I | 4 | 2 | 3 |
aKaplan-Meier estimate.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2011 ASCO Annual Meeting
First Author: G. Saglio
2024 ASCO Gastrointestinal Cancers Symposium
First Author: John Raymond Zalcberg
2013 ASCO Annual Meeting
First Author: Giuseppe Saglio
2012 ASCO Annual Meeting
First Author: Jeffrey Howard Lipton